CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) was awarded a five year contract (base year plus 4 option years) having a value of up to $12.2 million by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Meridian will manufacture up to 10 clinical experimental vaccines per year at its biopharmaceutical facility located in Memphis, TN. Meridian will be working closely with the Laboratory of Infectious Diseases (LID) of the NIAID, which has a long history of vaccine development and identification of new agents of viral diseases.
